

Prof. Dr. med. Michael Thomas

Affiliation

Head, Dpt. Thoracic Oncology,
Thoraxklinik Heidelberg, Amalienstraße 5, 69126 Heidelberg
Professor (W3), Medical Oncology of Thoracic Malignancies,
University of Heidelberg
Phone 06221/396-1301, Fax 06221/396-1302,
mail: michael.thomas@med.uni-heidelberg.de



Qualification and Board Certification

2006	Board Certification, Palliative Medicine, University Heidelberg
1996	Board Certification, Pneumology, University Münster
1996	Board Certification, Intensive Care, University Münster
1994	Board Certification, Hematology / Oncology, University Münster
1992	Board Certification, Internal Medicine, University Düsseldorf

Professional career

Since 2016	Board of Directors, Working Group on Medical Oncology, German Cancer Society
Since 2015	Board of Directors, National Center on Tumor Diseases (NCT), Heidelberg
Since 2011	Co-Coordinator, Disease Area Lung Cancer, German Center on Lung Research (DZL); Excellence Initiative of the German Ministry of Education and Research (BMBF)
Since 2005	Head, Dpt. Thoracic Oncology, Thoraxklinik Heidelberg
Since 2005	Professor (W3), Med. Oncology of Thoracic Malignancies, University Heidelberg
2010 - 2016	Coordinator, Working Group on Thoracic Oncology, German Cancer Society
2007 - 2009	Board of Directors, German Respiratory Society
2006 - 2013	Co-Chair, ABC (Aktion Bronchialkarzinom) – Clinical Trials Group on Lung Cancer
2004 - 2005	Professor (C3), Pulmonology - Internal Medicine, University Münster
1997 - 2005	Consultant / Associate Professor, Internal Medicine, University Münster
1995 - 2003	Head Coordinator, German Lung Cancer Cooperative Group (GLCCG).
1994 - 1996	Fellowship, Pulmonology, University Hospital Münster
1992 - 1995	Coordinator, German Lung Cancer Cooperative Group (GLCCG).
1992 - 1994	Fellowship, Hematology / Oncology, University Hospital Münster
1987 - 1992	Residency, Internal Medicine, University Hospital Düsseldorf
1986 - 1987	Internship, Internal Medicine, Ev. Krankenhaus Gießen
1979 - 1985	Medical School, University of Gießen

Major Field of Research

Conception, conduction and coordination of clinical trials and biomarker exploration in the field of lung cancer; impact of palliative care interventions throughout the lung cancer disease trajectory

Honors & Awards	2010	John-Mendelsohn - Clinical Trial Award - German Cancer Society
	2002	AIO-German Cancer Society Award

Memberships / Board activities

German Cancer Society	Certification Board / German Lung Cancer Centers
German Society of Palliative Medicine	Committee / German Lung Cancer Guidelines
German Society of Hematology / Oncology	International Association on the Study of Lung Cancer
German Society of Respiratory Medicine	American Society of Clinical Oncology
European Respiratory Society	European Society of Medical Oncology

Third party Funding (last 5 years)

2011-14	CANCERIALIA – Novel therapeutic approaches in lung cancer
2014-17	POSITIVE – Physical Exercise Program in lung cancer patients undergoing palliative treatment (assessment of fitness, self-efficacy and QoL) – Phase III-trial
2012-20	Dt. Zentrum für Lungenforschung, Disease Area Lung Cancer, Thoraxklinik BMBF-funded Health Center Excellence Initiative

Selected Publications

1. **Thomas M**, Rube C, Hoffknecht P, Macha HN, Freitag L, Linder A, Willich N, Hamm M, Sybrecht GW, Ukena D, Deppermann KM, Dröge C, Riesenbeck D, Heinecke A, Sauerland C, Junker K, Berdel WE, Semik M, for the German Lung Cancer Cooperative Group (2008). Impact of preoperative chemoradiation in addition to pre-operative chemotherapy: a randomised trial in stage III non-small cell lung cancer. *Lancet Oncology* 9: 636-648.
2. Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, **Thomas M** (2013): Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. *Ann Oncol* 22: 986-992
3. Reinmuth N, Stumpf A, Stumpf P, Muley T, Kobinger S, Hoffmann H, Herth FJ, Schnabel PA, Warth A, Bischoff H, **Thomas M** (2013): Characteristics and outcome of patients with second primary lung cancer. *Eur Respir J* 42: 1668-1676.
4. Shaw A, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, de Pas T, Besse B, Solomon BJ, Blackhall F, Wu Y-L, **Thomas M**, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA (2013): Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. *N Engl J Med* 20: 2385-2394
5. **Thomas M**, Fischer J, Andreas S, Kortsik C, Grah C, Serke M, von Eiff M, Witt C, Kollmeier J, Müller E, Schenk M, Schröder M, Villalobos M, Reinmuth N, Penzel R, Schnabel P, Acker T, Reuss A, Wolf M (2015): Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous non-small cell lung cancer. *Eur Respir J* 46: 219-229.
6. Schneider MA, Muley T, Kahn NC, Warth A, **Thomas M**, Herth FJ, Dienemann H, Meister M (2016): Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. *Oncotarget*. 7: 71285-71297
7. **Thomas M**, Sadjadian P, Kollmeier J, Lowe J, Mattson P, Trout JR, Gargano M, Patchen ML, Walsh R, Beliveau M, Marier, JF, Bose N, Gorden K, Schneller F (2017): A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. *Invest New Drugs* 35: 345-358.
8. Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, **Thomas M**, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA (2017): Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating *EGFR* mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. *Lancet Respir Med* 5: 435-444
9. Christopoulos P, Engel-Riedel W, Grohe C, Kropf-Sanchen C, von Pawel J, Gütz S, Kollmeier J, Eberhardt W, Ukena D, Baum V, Nimmrich I, Sieder C, Schnabel P, M. Serke M., **Thomas M** (2017) Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. *Ann Oncol*. 28: 1898-1902.
10. **Thomas M.**, Ponce-Aix S., Navarro A., Riera-Knorrenschild J., Schmidt M., Wiegert E., Kapp K., Wittig B., Mauri C., Dómine Gómez M., Kollmeier J., Sadjadian P., Fröhling K.-P., Huber R., Wolf M., IMPULSE study team (2018): Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study. *Annals of Oncology* 29: 2076-2084.
11. Christopoulos P., Endris V., Bozorgmehr F., Elsayed M., Kirchner M., Ristau J., Buchhalter I., Penzel R., Herth F.J., Heussel C.P., Eichhorn M., Muley T., Meister M., Fischer J.R., Rieken S., Warth A., Bischoff H., Schirmacher P., Stenzinger A., **Thomas M.** (2018): EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer. *Int J Cancer* 142: 2589-2598.
12. Christopoulos P., Kirchner M., Bozorgmehr F., Endris V., Elsayed M., Budczies J., Ristau J., Penzel R., Herth F.J., Heussel C.P., Eichhorn M., Muley T., Meister M., Fischer J.R., Rieken S., Lasitschka F., Bischoff H., Sotillo R., Schirmacher P., **Thomas M.**, Stenzinger A. (2019): Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma. *Int J Cancer*. 144: 190-199.
13. J. Budczies J., Allgäuer M., Litchfield K., Rempel E., Christopoulos P., Kazdal D., Endris V., **Thomas M.**, Fröhling S., Peters S., Swanton C., Schirmacher P., Stenzinger A. (2019): Optimizing panel-based tumor mutational burden (TMB) measurement. *Annals of Oncology (in press)*. doi: 10.1093/annonc/mdz205